首页 Inovio制药(usINO)-基本信息

Inovio制药(usINO)-基本信息

日报更新时间:04-15 10:22

周报更新时间:04-11 03:39

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

中文名称:Inovio制药


英文名称:Inovio Pharmaceuticals


简介:Inovio Pharmaceuticals, Inc.最初成立于1983年6月29日,按照加利福尼亚州法律以生物科技实验公司之名注册


电话:1-267-4404200


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 持股信息
  • 领导人信息

Inovio Pharmaceuticals主要从事治疗癌症、传染病的合成疫苗及免疫疗法的研发,公司以DNA为基础的SynCon技术,设计用于提供保护已知​​及新的病原株,如流感;穿孔DNA传输技术采用可控的电子脉冲以加速细胞的DNA疫苗吸收;公司的临床实验包括HPV引起的前癌与癌症、流感、前列腺癌、乳腺癌、肺癌、胰腺癌、丙型肝炎病毒、乙型肝炎病毒、HIV、疟疾的疫苗,且临床研究季节性、大流行流感疫苗及Zika病毒(译作:寨卡病毒、兹卡病毒、赛卡病毒)、埃博拉病毒疫苗和其他产品。Inovio Pharmaceuticals(INO)近期报道:世界卫生组织专家表示,Zika病毒正在美洲扩散,将感染300-400万人。Zika病毒由蚊虫传播,目前已从轻微威胁升级到警戒状态。该病毒没有疫苗,Zika病毒造成胎儿畸形,使得新生儿头部畸形偏小。巴西已出现了3,893例新生儿头部畸形偏小。2016年1月28日,Inovio制药公司(INO)宣布将与韩国的GeneOne Life Sciense(KSE:011000)合作研究治疗和预防ZIKA的疫苗,两公司之前曾合作研究过包括MERS和埃博拉病毒。

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
State Street Global Advisors 876212 0.89% 71400 8.87% 2019-07-31
ARK Investment Management LLC 2929597 2.99% 1043956 55.36% 2019-03-31
Sumitomo Mitsui Trust Holdings Inc 3189209 3.25% 3189209 -- 2019-03-31
Nikko Asset Management Americas Inc 3262519 3.33% 3262519 -- 2019-03-31
BlackRock Fund Advisors 4164981 4.22% 1108 0.03% 2019-07-31
State Street Corporation 4187183 4.27% 818624 24.30% 2019-03-31
Vanguard Group Inc 4825182 4.92% 278075 6.12% 2019-03-31
Wasatch Advisors Inc. 5848410 5.97% 510480 9.56% 2019-03-31
BlackRock Inc 7373473 7.52% 121548 1.68% 2019-03-31
SSGA Funds Management Inc 2703891 2.74% -2574 -0.10% 2019-07-31
Vanguard Investments Australia Ltd 2594739 2.63% 3897 0.15% 2019-07-31
Northern Trust Investments Inc 1684608 1.71% -12348 -0.73% 2019-07-31
Dimensional Fund Advisors, Inc. 1203099 1.23% 465137 63.03% 2019-03-31
Geode Capital Management, LLC 1131213 1.15% -876977 -43.67% 2019-03-31
Northern Trust Corp 1079202 1.10% 30694 2.93% 2019-03-31
Northern Trust Investments N A 1079202 1.10% 30694 2.93% 2019-03-31
Panagora Asset Management Inc 1060425 1.08% 342966 47.80% 2019-03-31
Fidelity Management & Research Company 1064938 1.08% 47514 4.67% 2019-07-31
D. E. Shaw & Co LP 1012896 1.03% -60190 -5.61% 2019-03-31
Dimensional Fund Advisors LP 916620 0.93% -- -- 2019-07-31
BlackRock Asset Management Canada Ltd 2123082 2.17% 937 0.04% 2019-05-31
Security Investors, LLC 573054 0.59% -445 -0.08% 2019-04-30
Guggenheim Capital LLC 577634 0.59% 72816 14.42% 2018-12-31
UBS Group AG 509241 0.52% 235965 86.35% 2018-12-31
Charles Schwab Investment Management Inc 491372 0.52% 5631 1.16% 2018-12-31
Deutsche Bank AG 542062 0.57% 81816 17.78% 2018-09-30
Fidelity SelectCo, LLC 432761 0.45% 54968 14.55% 2018-11-30
Citadel Advisors Llc 465619 0.49% 14609 3.24% 2018-06-30
BlackRock Institutional Trust Company NA 2415159 2.53% 42369 1.79% 2018-06-30
FMR Inc 399500 0.42% 399500 -- 2018-09-30
Vident Investment Advisory, LLC 398345 0.42% 106632 36.55% 2018-03-31
Allianz Global Investors Mnged Accounts 214960 0.24% 214960 -- 2018-06-30
Allianz Asset Management AG 214960 0.24% -1243 -0.57% 2018-06-30
Teachers Advisors Inc 216649 0.24% -- -- 2018-06-30
Allianz Global Investors 216203 0.24% -3659 -1.66% 2018-03-31
UBS Securities LLC 287360 0.31% -155533 -35.12% 2018-06-30
State Street Corp 3920321 4.29% -550651 -12.32% 2018-06-30
Renaissance Technologies Corp 311681 0.34% -38100 -10.89% 2018-06-30
Northern Trust Asset Management 206247 0.23% -1100 -0.53% 2018-07-31
BNY Mellon Investment Management 207227 0.23% -18770 -8.31% 2018-06-30
Citigroup Inc 193720 0.21% -21741 -10.09% 2018-03-31
Parametric Portfolio Associates LLC 209445 0.23% -15560 -6.92% 2018-03-31
Numeric Investors LLC 332484 0.37% -1216 -0.36% 2017-12-31
Virtus ETF Advisers LLC 174782 0.25% -3829 -2.14% 2018-03-22
Bellevue Asset Management AG 154703 0.18% 37 0.02% 2017-11-30
Millennium Management LLC 1183557 1.31% 340297 40.35% 2017-09-30
Morgan Stanley Smith Barney LLC 631163 0.70% 43475 7.40% 2017-09-30
Morgan Stanley & Co Inc 255375 0.28% 22643 9.73% 2017-09-30
TIAA-CREF Investment Management LLC 338476 0.37% 157651 87.18% 2017-09-30
GSA Capital Partners LLP 132000 0.17% 132000 -- 2017-06-30
Invesco PowerShares Capital Mgmt LLC 797317 1.08% 127287 19.00% 2016-09-30
Susquehanna Financial Group, LLLP 299101 0.40% -64243 -17.68% 2016-09-30
BlackRock Advisors LLC 259397 0.35% -6720 -2.53% 2016-09-30
Stoneridge Investment Partners LLC 252376 0.34% 77636 44.43% 2016-09-30
Arrowstreet Capital Limited Partnership 240113 0.32% 240113 -- 2016-09-30
New York State Common Retirement Fund 230458 0.31% 56631 32.58% 2016-09-30
Emerald Advisers Inc 203737 0.28% 48751 31.46% 2016-09-30
Putnam Investment Management,LLC 161600 0.22% -- -- 2016-09-30
J. Joseph Kim 3348299 3.00% 24442583 0.10% 1999-11-30
Blackrock, Inc. 3590287 3.00% 26209095 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
NT R2000 Growth Index Fund - Lending 262400 0.27% 4600 1.78% 2019-06-30
iShares Nasdaq Biotechnology ETF 961632 0.98% -2852 -0.30% 2019-07-30
Vanguard Extended Market Index Fund 1276663 1.29% 2800 0.22% 2019-06-30
iShares Russell 2000 ETF 2020565 2.05% 3960 0.20% 2019-07-30
Wasatch Small Cap Growth Fund 2153878 2.18% -- -- 2019-06-30
Wasatch Ultra Growth Fund 2193841 2.23% 1034430 89.22% 2019-06-30
Vanguard Total Stock Market Index Fund 2571400 2.61% 4032 0.16% 2019-06-30
SPDR 2630391 2.67% -2574 -0.10% 2019-06-21
ARK Genomic Revolution ETF 3955017 4.01% 162286 4.28% 2019-06-30
iShares Russell 2000 Growth ETF 831813 0.84% -- -- 2019-07-30
Wasatch Micro Cap Fund 622873 0.63% -- -- 2019-06-30
Schwab US Small-Cap ETF 267666 0.27% 228 0.09% 2019-07-31
Guggenheim Mid Cap Value Fund 285661 0.29% -- -- 2019-03-31
NT R2000 Index Fund - NL 321477 0.33% -9540 -2.88% 2019-06-30
Fidelity 343188 0.35% 47637 16.12% 2019-04-30
State Street Russell Small Cap 349840 0.35% -- -- 2019-07-31
NT R2000 Growth Index Fund - Non-Lending 352153 0.36% -25652 -6.79% 2019-06-30
DFA US Small Cap Portfolio 387915 0.39% -- -- 2019-05-31
State Street Russell Small/Mid Cap 423117 0.43% 69400 19.62% 2019-07-31
Direxion Daily S&P Biotech Bull 3X Shrs 258775 0.26% 70218 37.24% 2019-04-30
iShares US Small Cap ETF (CAD-Hedged) 1794455 1.83% -3015 -0.17% 2019-05-30
ARK Genomic Revolution Multi-Sector ETF 3417798 3.49% 504461 17.32% 2019-04-30
iShares Micro-Cap ETF 207505 0.21% -- -- 2019-03-29
Northern Trust Russell 2000 Index DC NL 211672 0.22% 726 0.34% 2019-02-28
Vanguard Health Care Index Fund 252879 0.26% 5110 2.06% 2019-02-28
DFA US Micro Cap Portfolio 206156 0.21% -- -- 2019-01-31
Loncar Cancer Immunotherapy ETF 161767 0.17% -290896 -64.26% 2018-06-20
Schwab Small Cap Index Fund 169240 0.18% -- -- 2019-01-31
Fidelity Advisor 399500 0.42% -- -- 2018-11-30
ARK Innovation ETF 184921 0.19% 184921 -- 2018-05-31
iShares Micro-Cap 218557 0.24% -- -- 2018-09-12
Schwab Small Cap Index 161062 0.18% -- -- 2018-07-31
Vanguard Total Stock Mkt Idx 2214985 2.42% 57093 2.65% 2018-07-31
iShares Nasdaq Biotechnology 1023498 1.15% -1947 -0.19% 2018-09-12
Wasatch Small Cap Growth Investor 1218886 1.33% -- -- 2018-06-30
Vanguard Extended Market Idx Inv 1127159 1.23% -- -- 2018-07-31
iShares Russell 2000 Growth 802246 0.90% -774 -0.10% 2018-09-12
State Street Russell Small/Mid Cap Idx Fd Cl I 228944 0.29% 27158 13.46% 2017-06-30
Wasatch Ultra Growth 384407 0.42% 141782 58.44% 2018-06-30
Guggenheim Mid Cap Value A 285661 0.31% -- -- 2018-07-31
Wasatch Micro Cap 252898 0.28% 40045 18.81% 2018-06-30
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 206247 0.23% -1100 -0.53% 2018-07-31
Vanguard Health Care ETF 192423 0.21% 1602 0.84% 2018-07-31
Fidelity Spartan 172664 0.19% 9408 5.76% 2018-04-30
BlackRock Extended Equity Market K 164811 0.18% 51094 44.93% 2018-06-30
Guggenheim Var Mid Cap Value (Series V) 141243 0.16% -- -- 2018-05-31
BioShares 178365 0.20% -- -- 2018-07-30
Vanguard Instl Ttl Stk Mkt Idx InstlPls 146636 0.16% -- -- 2018-05-31
CREF Stock R1 146222 0.16% -- -- 2018-01-31
The Vanguard Russell 2000 Growth Index 132849 0.15% -- -- 2018-01-31
AXA 2000 Managed Volatility K 121423 0.13% -- -- 2017-10-31
BlackRock Russell 2000 123796 0.14% 27688 28.81% 2017-09-30
BlackRock Russell 2500 123944 0.14% 34508 38.58% 2017-09-30
iShares Russell 2000 (AU) 1180183 1.90% -723 -0.10% 2015-11-27
Fidelity Spartan® Extended Mkt Indx Fd 243066 0.30% -- -- 2015-10-31
Vanguard Instl Total Stock Market Index 203107 0.30% -- -- 2015-10-31
BB Adamant Global Biotech 200000 0.30% -- -- 2015-07-31
CREF Stock Account 185842 0.30% -- -- 2015-09-30
SSgA Russell Small/Mid Cap Index Fund Tr 172500 0.20% 28700 20.00% 2015-06-30
Putnam Global Health Care Fund 146000 0.20% -- -- 2015-09-30
SPDR® S&P Biotech ETF 3351664 5.40% 10536 0.30% 2015-11-27

Morton C. Collins Dr. Mort C. Collins is Independent Director at Inovio Pharmaceuticals, Inc., General Partner at Innovation Valley Partners LP, General Partner at BVP Partners LLC, Lead Independent Director at Kopin Corp., Chairman at 360ip Pte Ltd., Chairman at CDI Bioscience, Inc., Chairman at PD-LD, Inc., Chairman at Ventaira Pharmaceuticals, Inc., a Member at Battelle Memorial Institute, a Member at Institute for Advanced Study, Inc., a Member at Princeton University and Member-Research Roundtable at National Academy of Sciences. He is on the Board of Directors at Inovio Pharmaceuticals, Inc., Kopin Corp., Advanced Cerametrics, Inc., Hepregen Corp., ImageTree Corp., Pharos LLC and Viral Genomics, Inc. Dr. Collins was previously employed as Partner by Cardinal Partners, Managing Partner by DSV Partners IV LP, General Partner by DSV Management LLC, Chairman by Government of the United States of America, Managing Partner by DSV Partners III, Managing Partner by DSV Associates, and Chairman & President by National Venture Capital Association. He also served on the board at VGX Pharmaceuticals, Inc., Strategic Diagnostics, Inc., Sypherlink, Inc. and Pharos Capital Group LLC. He received his undergraduate degree from the University of Delaware, a graduate degree from Princeton University and a doctorate degree from Princeton University.
Simon X. Benito Presently, Simon X. Benito is Chairman for Inovio Pharmaceuticals, Inc. He is also on the board of DURECT Corp. He previously was Senior Vice President-Vaccine Division at Merck & Co., Inc. Executive Vice President of Merck-Medco Managed Care LLC and Executive Director & Vice President at Merck Human Health US (both are subsidiaries of Merck & Co., Inc.).
Lota S. Zoth Lota S. Zoth is on the board of NewLink Genetics Corp., Zymeworks, Inc., Inovio Pharmaceuticals, Inc. and Spark Therapeutics, Inc. In her past career Ms. Zoth held the position of Chief Financial Officer & Senior Vice President at Medimmune, Inc., Vice President-Finance for Marriott International, Inc., Chief Accounting Officer & Controller at PepsiCo, Inc., Chairman of Orexigen Therapeutics, Inc., Chief Financial Officer & Senior Vice President for MedImmune LLC, Auditor at Ernst & Young LLP (Missouri), Chief Accounting Officer, VP & Controller for Sodexho Marriott Services, Inc. and Senior Vice President & Controller at PSINet, Inc. She received an undergraduate degree from Texas Tech University.
George W. Bickerstaff Mr. George W. Bickerstaff, III, is an Independent Director at Innoviva, Inc., a Chairman at Optical Academy LLC, an Independent Director at Inovio Pharmaceuticals, Inc., a Chairman at Cardax, Inc., an Independent Director at CareDx, Inc., a Managing Director at CRT Investment Banking LLC, a Managing Director at M.M. Dillon & Co. and a Chairman at Cyclica, Inc. He is on the Board of Directors at Axovant Sciences Ltd., Innoviva, Inc., Inovio Pharmaceuticals, Inc., Viventia Bio, Inc., CareDx, Inc., GAVI Alliance, International Vaccine Institute, Roivant Sciences GmbH, The Center for Disease Dynamics, Economics & Policy and The International Centre for Missing & Exploited Children. Mr. Bickerstaff was previously employed as an Independent Director by ARIAD Pharmaceuticals, Inc., a Managing Director by CRT Capital Group LLC, a Chief Financial Officer by Novartis Pharma AG, a Chief Financial Officer by Novartis Pharma NV, a Finance Director by Sandoz-Wander Pharma AG, a Chief Financial Officer & Executive Vice President by Workscape, Inc., a Chief Financial Officer & Executive Vice President by Uniscribe Professional Services, Inc., a Chief Financial Officer & Executive Vice President by Intellisource Group, Inc., a Vice President-Finance by Cognizant Corp, a Chief Financial Officer by IMS Healthcare, Inc., and a Chief Financial Officer by Quintiles IMS, Inc. He also served on the board at Cardax Pharmaceuticals, Inc., Oracle Healthcare Acquisition Corp., Vion Pharmaceuticals, Inc., Amazys Holding AG, ARIAD Pharmaceuticals, Inc., BMP Sunstone Corp. and Viventia Biotech, Inc. He received his undergraduate degree from Rutgers State University of New Jersey and a graduate degree from Harvard University.
Morton C. Collins Dr. Mort C. Collins is Independent Director at Inovio Pharmaceuticals, Inc., General Partner at Innovation Valley Partners LP, General Partner at BVP Partners LLC, Lead Independent Director at Kopin Corp., Chairman at 360ip Pte Ltd., Chairman at CDI Bioscience, Inc., Chairman at PD-LD, Inc., Chairman at Ventaira Pharmaceuticals, Inc., a Member at Battelle Memorial Institute, a Member at Institute for Advanced Study, Inc., a Member at Princeton University and Member-Research Roundtable at National Academy of Sciences. He is on the Board of Directors at Inovio Pharmaceuticals, Inc., Kopin Corp., Advanced Cerametrics, Inc., Hepregen Corp., ImageTree Corp., Pharos LLC and Viral Genomics, Inc. Dr. Collins was previously employed as Partner by Cardinal Partners, Managing Partner by DSV Partners IV LP, General Partner by DSV Management LLC, Chairman by Government of the United States of America, Managing Partner by DSV Partners III, Managing Partner by DSV Associates, and Chairman & President by National Venture Capital Association. He also served on the board at VGX Pharmaceuticals, Inc., Strategic Diagnostics, Inc., Sypherlink, Inc. and Pharos Capital Group LLC. He received his undergraduate degree from the University of Delaware, a graduate degree from Princeton University and a doctorate degree from Princeton University.
Wendy L. Yarno Ms. Wendy L. Yarno is an Independent Director at Global Blood Therapeutics, Inc., an Independent Director at Inovio Pharmaceuticals, Inc., an Independent Director at Alder Biopharmaceuticals, Inc. and an Independent Director at MyoKardia, Inc. She is on the Board of Directors at Global Blood Therapeutics, Inc., Inovio Pharmaceuticals, Inc., Alder Biopharmaceuticals, Inc. and MyoKardia, Inc. Ms. Yarno was previously employed as a Non-Executive Chairman by Aratana Therapeutics, Inc., an Independent Director by Medivation, Inc., a Chief Marketing Officer by HemoShear LLC, a Chief Marketing Officer & Executive Vice President by Merck & Co., Inc., a Vice President-Women's Health Care Franchise by Johnson & Johnson, and a Vice President by Ortho-McNeil Pharmaceutical LLC. She also served on the board at Durata Therapeutics, Inc., PluroGen Therapeutics LLC, ADial Pharmaceuticals LLC and St. Jude Medical LLC. She received her undergraduate degree from Portland State University and an MBA from Fox School of Business.
Avtar S. Dhillon Avtar S. Dhillon is a businessperson who founded OncoSec Medical, Inc. and Vitality Biopharma, Inc. and who has been at the helm of 9 different companies. Presently, he holds the position of Non-Executive Chairman of OncoSec Medical, Inc., Executive Chairman & President at Emerald Health Pharmaceuticals, Inc., Non-Executive Chairman at Inovio Pharmaceuticals, Inc., Chairman for Nemus Bioscience, Inc., Chairman, President & Chief Executive Officer at Emerald Health Sciences, Inc. and Executive Chairman & President at Emerald Health Therapeutics, Inc. Dr. Dhillon is also on the board of Arch Biosurgery, Inc., Cannabis Canada Association and Emerald Health Bioceuticals, Inc. and Member of Canadian Medical Association, Member of College of Physicians & Surgeons of BC and Member of College of Family Practitioners. In the past he occupied the position of Chairman at Vitality Biopharma, Inc., Chairman of Arch Therapeutics, Inc., Member of Doctors of BC, President & Chief Executive Officer for Genetronics Biomedical Corp. and Vice President & Investment Manager at Lumira Capital Investment Management, Inc. Avtar S. Dhillon received a doctorate and an undergraduate degree from the University of British Columbia.
Peter D. Kies Peter D. Kies occupies the position of Chief Financial & Accounting Officer at Inovio Pharmaceuticals, Inc. In the past Mr. Kies held the position of Chief Financial Officer of Genetronics Biomedical Corp., Chief Financial Officer at Newgen Results Corp., Controller at Cytel Corp. and Auditor of Ernst & Young LLP. He received an undergraduate degree from Alliant International University.
Angel Cabrera Angel Cabrera is President of George Mason University, Member of Greater Phoenix Leadership, Inc., Member of Forum of Young Global Leaders, Member of The Future Trends Forum and Member of Council on Foreign Relations, Inc. and on the board of 13 other companies. In the past Angel Cabrera occupied the position of Chief Technology Officer at Vurv Technology, Inc., Change Management Consultant at Accenture LLC, President for Thunderbird School of Global Management and Professor & Dean at Instituto de Empresa SL. Angel Cabrera received a doctorate and a graduate degree from Georgia Institute of Technology and an undergraduate degree and a graduate degree from Universidad Polit�0�1�0�8cnica de Madrid.
Laurent M. Humeau Laurent M. Humeau holds the position of Chief Scientific Officer for Inovio Pharmaceuticals, Inc. Dr. Humeau previously occupied the position of Vice President-Research & Development at VIRxSYS Corp. and Senior Director-Translational Research at Intrexon Corp. Laurent M. Humeau received a doctorate from Universit�0�1�0�8 Paris Diderot-Paris 7 and a graduate degree and an undergraduate degree from Universit�0�1�0�8 Pierre et Marie Curie.
J. Joseph Kim Founder of VGX Pharmaceuticals LLC, J. Joseph Kim is President, Chief Executive Officer & Director at Inovio Pharmaceuticals, Inc. He is also on the board of International Vaccine Institute and Council of Korean Americans and Member-Global Agenda Council at Forum Mondial de L'Economie, Member of Aspen Global Leadership Network and Member of The Aspen Institute, Inc. In the past J. Joseph Kim occupied the position of President & Chief Executive Officer of VGX Pharmaceuticals LLC. Dr. Kim received a doctorate from the University of Pennsylvania, an undergraduate degree from Massachusetts Institute of Technology and an MBA from The Wharton School of the University of Pennsylvania.
Morton C. Collins Dr. Mort C. Collins is Independent Director at Inovio Pharmaceuticals, Inc., General Partner at Innovation Valley Partners LP, General Partner at BVP Partners LLC, Lead Independent Director at Kopin Corp., Chairman at 360ip Pte Ltd., Chairman at CDI Bioscience, Inc., Chairman at PD-LD, Inc., Chairman at Ventaira Pharmaceuticals, Inc., a Member at Battelle Memorial Institute, a Member at Institute for Advanced Study, Inc., a Member at Princeton University and Member-Research Roundtable at National Academy of Sciences. He is on the Board of Directors at Inovio Pharmaceuticals, Inc., Kopin Corp., Advanced Cerametrics, Inc., Hepregen Corp., ImageTree Corp., Pharos LLC and Viral Genomics, Inc. Dr. Collins was previously employed as Partner by Cardinal Partners, Managing Partner by DSV Partners IV LP, General Partner by DSV Management LLC, Chairman by Government of the United States of America, Managing Partner by DSV Partners III, Managing Partner by DSV Associates, and Chairman & President by National Venture Capital Association. He also served on the board at VGX Pharmaceuticals, Inc., Strategic Diagnostics, Inc., Sypherlink, Inc. and Pharos Capital Group LLC. He received his undergraduate degree from the University of Delaware, a graduate degree from Princeton University and a doctorate degree from Princeton University.
Morton C. Collins Dr. Mort C. Collins is Independent Director at Inovio Pharmaceuticals, Inc., General Partner at Innovation Valley Partners LP, General Partner at BVP Partners LLC, Lead Independent Director at Kopin Corp., Chairman at 360ip Pte Ltd., Chairman at CDI Bioscience, Inc., Chairman at PD-LD, Inc., Chairman at Ventaira Pharmaceuticals, Inc., a Member at Battelle Memorial Institute, a Member at Institute for Advanced Study, Inc., a Member at Princeton University and Member-Research Roundtable at National Academy of Sciences. He is on the Board of Directors at Inovio Pharmaceuticals, Inc., Kopin Corp., Advanced Cerametrics, Inc., Hepregen Corp., ImageTree Corp., Pharos LLC and Viral Genomics, Inc. Dr. Collins was previously employed as Partner by Cardinal Partners, Managing Partner by DSV Partners IV LP, General Partner by DSV Management LLC, Chairman by Government of the United States of America, Managing Partner by DSV Partners III, Managing Partner by DSV Associates, and Chairman & President by National Venture Capital Association. He also served on the board at VGX Pharmaceuticals, Inc., Strategic Diagnostics, Inc., Sypherlink, Inc. and Pharos Capital Group LLC. He received his undergraduate degree from the University of Delaware, a graduate degree from Princeton University and a doctorate degree from Princeton University.
David B. Weiner Founder of Inovio Pharmaceuticals, Inc., David B. Weiner is on the board of Inovio Pharmaceuticals, Inc. and Executive Vice President at The Wistar Institute. Dr. Weiner previously occupied the position of Professor at the University of Pennsylvania. He received a doctorate from The University of Cincinnati College of Medicine, a graduate degree from the University of Cincinnati (Ohio) and an undergraduate degree from State University of New York at Albany.
Mark C. Twyman Mark C. Twyman is Vice President-Commercial at Inovio Pharmaceuticals, Inc. In the past he was Chief Commercial Officer at GI Dynamics, Inc., Vice President-Marketing for Novavax, Inc. and Vice President & General Manager at MedImmune LLC. Mr. Twyman received an undergraduate degree from Dickinson College and an MBA from The Wharton School of the University of Pennsylvania.
Angel Cabrera Angel Cabrera is President of George Mason University, Member of Greater Phoenix Leadership, Inc., Member of Forum of Young Global Leaders, Member of The Future Trends Forum and Member of Council on Foreign Relations, Inc. and on the board of 13 other companies. In the past Angel Cabrera occupied the position of Chief Technology Officer at Vurv Technology, Inc., Change Management Consultant at Accenture LLC, President for Thunderbird School of Global Management and Professor & Dean at Instituto de Empresa SL. Angel Cabrera received a doctorate and a graduate degree from Georgia Institute of Technology and an undergraduate degree and a graduate degree from Universidad Polit�0�1�0�8cnica de Madrid.
Angel Cabrera Angel Cabrera is President of George Mason University, Member of Greater Phoenix Leadership, Inc., Member of Forum of Young Global Leaders, Member of The Future Trends Forum and Member of Council on Foreign Relations, Inc. and on the board of 13 other companies. In the past Angel Cabrera occupied the position of Chief Technology Officer at Vurv Technology, Inc., Change Management Consultant at Accenture LLC, President for Thunderbird School of Global Management and Professor & Dean at Instituto de Empresa SL. Angel Cabrera received a doctorate and a graduate degree from Georgia Institute of Technology and an undergraduate degree and a graduate degree from Universidad Polit�0�1�0�8cnica de Madrid.
Jessica C. Lee Currently, Jessica C. Lee occupies the position of VP-Clinical Operations & Global Integration at Inovio Pharmaceuticals, Inc. She received a graduate degree from Drexel University School of Public Health, a graduate degree from Temple University School of Pharmacy and an undergraduate degree from Drexel University.
Jennifer Laux Ms. Jennifer Laux is Vice President-Commercial Development at Inovio Pharmaceuticals, Inc. Ms. Laux was previously employed as Vice President-Cardiovascular Marketing by Boehringer Ingelheim Corp. She received her undergraduate degree from Georgetown University, a graduate degree from the University of Pennsylvania and an MBA from The Wharton School of the University of Pennsylvania.
Maggie Campbell Maggie Campbell is Director-Finance at Inovio Pharmaceuticals, Inc.
Jacqueline E. Shea Presently, Jacqueline E. Shea holds the position of Chief Operating Officer & Executive Vice President for Inovio Pharmaceuticals, Inc. In the past she held the position of Vice President-Europe Business Development at Emergent BioSolutions, Inc. and Chief Executive Officer of Aeras Global TB Vaccine Foundation. She received a doctorate from The National Institute For Medical Research and an undergraduate degree from the University of Bath.
Scott M. White Scott M. White is Vice President-Clinical Development at Inovio Pharmaceuticals, Inc. Dr. White previously was Assistant Professor at the University of Pittsburgh School of Medicine and Assistant Professor at Baylor College of Medicine. Scott M. White received a doctorate from Pennsylvania State University College of Medicine and an undergraduate degree from The Pennsylvania State University.
Prakash Bhuyan Prakash Bhuyan is Vice President-Clinical Development at Inovio Pharmaceuticals, Inc. Dr. Bhuyan received an MBA and a doctorate from The University of Texas Southwestern Medical Center.
Jeffrey Skolnik Jeffrey Skolnik is Vice President-Clinical Development at Inovio Pharmaceuticals, Inc. In the past Dr. Skolnik occupied the position of Chief Medical Officer for TetraLogic Pharmaceuticals Corp. and Principal at GlaxoSmithKline Plc. He received a doctorate from New York University.
Ami Shah Brown Ami Shah Brown occupies the position of Vice President-Regulatory Affairs for Inovio Pharmaceuticals, Inc. She previously held the position of Assistant Professor at George Washington University. Dr. Brown received a doctorate from Johns Hopkins Bloomberg School of Public Health, a graduate degree from Emory University and an undergraduate degree from the University of Pennsylvania.
Paul Stead Dr. Paul Stead is Vice President-Business Development at Adaptimmune Therapeutics Plc and Vice President-Business Development at Inovio Pharmaceuticals, Inc. Dr. Stead was previously employed as Vice President-Business Development by Nimbus Therapeutics LLC. He received his undergraduate degree from the University of Bath, a graduate degree from The University of Nottingham and an MBA from Lehigh University.
Ben Matone Currently, Ben Matone occupies the position of Director-Investor Relations of Inovio Pharmaceuticals, Inc.
Shawn D. Bridy Shawn D. Bridy is Vice President-Business Development for Inovio Pharmaceuticals, Inc. Mr. Bridy received a graduate degree and an MBA from Villanova University.
Ann Calby Miller Ann Calby Miller is on the board of Inovio Pharmaceuticals, Inc. In the past Dr. Miller held the position of Senior Vice President-Pharmaceutical Services at Eisai Co., Ltd. He received an undergraduate degree from Duke University and a doctorate from Duke University School of Medicine.

量化对比

全部评论 36

  • 美股抗癌医药股集体上涨,Merrimack制药涨超8%,Inovio制药盘中一度涨17%,Seagen涨超4%,精密科学涨超2%,Biogen制药涨近2%。

  • 美股抗议概念股涨幅居前,诺瓦瓦克斯医药(NVAX.O)涨超11%,Moderna(MRNA.O)涨5.72%,BioNTech SE(BNTX.O)涨4.72%,Vir Biotechnology(VIR.O)涨3.40%,Inovio制药(INO.O)涨超3%。

  • 美股抗议概念股涨幅居前,诺瓦瓦克斯医药(NVAX.O)涨超11%,Moderna(MRNA.O)涨5.72%,BioNTech SE(BNTX.O)涨4.72%,Vir Biotechnology(VIR.O)涨3.40%,Inovio制药(INO.O)涨超3%。

  • 抗疫概念股跌幅居前,Vir Biotechnology(VIR.O)跌超31%,Moderna(MRNA.O)跌超8%,Vaxart(VXRT.O)跌7.7%,Inovio制药(INO.O)跌超5%,诺瓦瓦克斯医药(NVAX.O)跌3.47%。

  • 抗疫概念股跌幅居前,Vir Biotechnology(VIR.O)跌超31%,Moderna(MRNA.O)跌超8%,Vaxart(VXRT.O)跌7.7%,Inovio制药(INO.O)跌超5%,诺瓦瓦克斯医药(NVAX.O)跌3.47%。

  • 美股抗疫概念股跌幅居前,诺瓦瓦克斯医药(NVAX.O)跌16.44%,Inovio制药(INO.O)跌12.37%,Vir Biotechnology(VIR.O)跌9.98%,Moderna(MRNA.O)跌6.46%。

  • Inovio制药(INO.O)盘前跌4.14%,2020年全年净亏损同比扩大40%。

  • Inovio制药(INO.O)盘后大涨14%。

  • Inovio制药(INO.O):第四季度营收560万美元,第四季度每股亏损0.14美元。

  • Inovio制药涨超15%,该股在最受欢迎做空榜单上排名第25,目前该美国散户论坛上的讨论量激增。

  • 美股抗疫概念股涨跌互现,诺瓦瓦克斯医药涨近4%,辉瑞现涨2.27%,Inovio Pharmaceuticals跌超7%,Moderna跌近4%,BioNTech SE跌2.94%,阿斯利康跌1.96%。

  • 美股抗疫概念股涨跌互现,Moderna涨超10%,Inovio Pharmaceuticals涨近8%;BioNTech SE跌10%,辉瑞跌近2%。

  • 【疫苗股普遍下跌,血浆类股涨跌各异】疫苗股里,Alpha Pro Tech收跌将近5.5%,Vaxart跌约3.8%,诺瓦瓦克斯跌超2.5%,辉瑞制药跌约1.6%,阿斯利康跌超1.4%,Moderna跌超1.2%,Inovio Pharmaceuticals则涨超3.9%,辉瑞合作伙伴BioNTech也涨超6.0%。血浆类股里,Thermogenesis Holdings收跌逾10.6%,iBio跌超3.8%,T2 Biosystems跌超3%,Liminal BioSciences则涨约1.9%,Cerus也涨超1.7%。

  • 美股抗疫概念股持续走高,阿索尔达生物制药涨近70%,诺瓦瓦克斯医药涨超10%,Inovio Pharmaceuticals涨超8%,Moderna涨超6%,BioNTech SE涨5.8%。

  • 美股抗疫概念股表现疲软,Inovio Pharmaceuticals跌超10%,联合保健产品跌超4%,Moderna跌1.6%。

  • 美股抗疫概念股盘前走高,诺瓦瓦克斯医药涨超7%,Moderna涨近5%,Inovio Pharmaceuticals涨5.2%。

  • 浑水宣布做空Inovio Pharmaceuticals,理由是法院最近对该公司的一项裁决及其股价近期大涨源于对新冠疫苗的“炒作”。法院的判决称,该公司“缺乏生产能力”,无法达到2020年生产100万剂、2021年生产1亿剂疫苗的目标。Inovio Pharmaceuticals股价今年迄今已大涨245%,目前跌8%。

  • Inovio Pharmaceuticals(INO.O)跌超17%,此前公布了INO-4800新冠疫苗中期第一阶段阳性数据。

  • Inovio Pharmaceuticals(INO.O)盘前跌近5%,此前公布了INO-4800新冠疫苗中期第一阶段阳性数据。

  • 美股抗疫概念股逆市走强,NanoViricides涨超15%,Inovio Pharmaceuticals涨超13%,Co-diagnostics涨超5%。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐